Clinical significance of SARS-CoV-2-specific IgG detection with a rapid antibody kit for COVID-19 patients.
COVID-19
IgG
PCR
SARS-CoV-2
a rapid kit
antibody
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
18
05
2020
revised:
07
08
2020
accepted:
10
08
2020
pubmed:
11
9
2020
medline:
16
1
2021
entrez:
10
9
2020
Statut:
ppublish
Résumé
The longitudinal observation of the detection of antibody responses to SARS-CoV-2 using antibody kits during the clinical course of COVID-19 is not yet fully investigated. To understand the significance of the detection of anti-SARS-CoV-2 antibodies, particularly IgG, using a rapid antibody kit, during the clinical course of COVID-19 patients with different severities. Sixty-three serum samples from 18 patients (5 asymptomatic and 13 symptomatic patients) were retrospectively examined using a commercial SARS-CoV-2 IgM/IgG antibody kit. PCR positivity of patient samples was also examined as a marker of current SARS-CoV-2 infection. IgG antibodies were detected in all cases in this study. The IgG detection rates reached 100.0% in samples collected on day 13 or later. IgG seropositivity after an initial negative status was observed in 13 patients (3/5 asymptomatic and 10/13 symptomatic cases). Interestingly, the persistence of both PCR and IgG positivity was detected in seven cases, of which three were asymptomatic. The longest overlap duration of the PCR and IgG positivity was 17 days in asymptomatic status. SARS-CoV-2-specific IgG production can be detected in all infected individuals, using a rapid antibody kit, irrespective of clinical status. However, these findings suggest that, in some infected individuals, particularly those with asymptomatic status, the presence of virus-specific IgG antibodies does not imply prompt viral clearance.
Sections du résumé
BACKGROUND
The longitudinal observation of the detection of antibody responses to SARS-CoV-2 using antibody kits during the clinical course of COVID-19 is not yet fully investigated.
OBJECTIVES
To understand the significance of the detection of anti-SARS-CoV-2 antibodies, particularly IgG, using a rapid antibody kit, during the clinical course of COVID-19 patients with different severities.
METHODS
Sixty-three serum samples from 18 patients (5 asymptomatic and 13 symptomatic patients) were retrospectively examined using a commercial SARS-CoV-2 IgM/IgG antibody kit. PCR positivity of patient samples was also examined as a marker of current SARS-CoV-2 infection.
RESULTS
IgG antibodies were detected in all cases in this study. The IgG detection rates reached 100.0% in samples collected on day 13 or later. IgG seropositivity after an initial negative status was observed in 13 patients (3/5 asymptomatic and 10/13 symptomatic cases). Interestingly, the persistence of both PCR and IgG positivity was detected in seven cases, of which three were asymptomatic. The longest overlap duration of the PCR and IgG positivity was 17 days in asymptomatic status.
CONCLUSIONS
SARS-CoV-2-specific IgG production can be detected in all infected individuals, using a rapid antibody kit, irrespective of clinical status. However, these findings suggest that, in some infected individuals, particularly those with asymptomatic status, the presence of virus-specific IgG antibodies does not imply prompt viral clearance.
Identifiants
pubmed: 32909661
doi: 10.1111/irv.12802
pmc: PMC7767946
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Reagent Kits, Diagnostic
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13-18Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
Clin Infect Dis. 2016 Aug 1;63(3):330-7
pubmed: 27118785
Influenza Other Respir Viruses. 2021 Jan;15(1):13-18
pubmed: 32909661
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
mBio. 2020 Mar 26;11(2):
pubmed: 32217609
Emerg Microbes Infect. 2020 Dec;9(1):833-836
pubmed: 32306864
J Med Virol. 2020 Sep;92(9):1518-1524
pubmed: 32104917
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
Lancet. 2020 Apr 4;395(10230):1101-1102
pubmed: 32247384
J Infect. 2020 Aug;81(2):318-356
pubmed: 32283147
J Microbiol Immunol Infect. 2020 Jun;53(3):485-487
pubmed: 32198005
J Infect. 2020 Jul;81(1):e28-e32
pubmed: 32283141
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
J Infect. 2020 Aug;81(2):e55-e58
pubmed: 32335168